Genetic and biochemical changes of the serotonergic system in migraine pathobiology

Claudia Francesca Gasparini\(^1\), Robert Anthony Smith\(^2\) and Lyn Robyn Griffiths\(^2*\)

**Abstract**

Migraine is a brain disorder characterized by a piercing headache which affects one side of the head, located mainly at the temples and in the area around the eye. Migraine imparts substantial suffering to the family in addition to the sufferer, particularly as it affects three times more women than men and is most prevalent between the ages of 25 and 45, the years of child rearing. Migraine typically occurs in individuals with a genetic predisposition and is aggravated by specific environmental triggers. Attempts to study the biochemistry of migraine began as early as the 1960s and were primarily directed at serotonin metabolism after an increase of 5-hydroxyindoleacetic acid (5-HIAA), the main metabolite of serotonin was observed in urine of migraineurs. Genetic and biochemical studies have primarily focused on the neurotransmitter serotonin, considering receptor binding, transport and synthesis of serotonin and have investigated serotonergic mediators including enzymes, receptors as well as intermediary metabolites. These studies have been mainly assayed in blood, CSF and urine as the most accessible fluids. More recently PET imaging technology integrated with a metabolomics and a systems biology platform are being applied to study serotonergic biology. The general trend observed is that migraine patients have alterations of neurotransmitter metabolism detected in biological fluids with different biochemistry from controls, however the interpretation of the biological significance of these peripheral changes is unresolved. In this review we present the biology of the serotonergic system and metabolic routes for serotonin and discuss results of biochemical studies with regard to alterations in serotonin in brain, cerebrospinal fluid, saliva, platelets, plasma and urine of migraine patients.

**Keywords:** Migraine with aura, Migraine without aura, Cortical spreading depression, Serotonin, Metabolomics, Melatonin, Tryptophan, Triptans, SERT, Kyneurine pathway

**Review**

**Introduction**

Migraine is a painful neurological disease whose manifestation results from an interplay of enviro-genomic factors and the severity of symptoms often propels sufferers to abuse medication. Migraine reigns as the 8th most burdensome disease in the world and the 4th most in women according to the 2012 Global Burden of Disease study [1]. The clinical features of migraine according to IHS classification include intense, pulsating head pain localized to one side of the head that can effectively disable its sufferer for up to 72 h [2]. Accompanying symptoms of migraine in addition to the headache include nausea, vomiting, and hypersensitivity to lights, sounds and/or smells, all of which can be aggravated by physical activity [2]. The disease is believed to develop in genetically vulnerable populations, disabling an estimated 12% of Caucasian people, varying in accordance with genetic background, climatic region, socioeconomic status, life-style, presence of other diseases and the general health of the sourced population [3, 4]. There is also a well-established overrepresentation of the disease in females, affecting ~3 times more females than males due to a complex interplay of hormonal and enviro-genomic exposures [5].

Migraine is diagnosed by specialized physicians utilizing the current International Headache Society (IHS)
Serotonergic biology and genetics

Biochemical, genetic and pharmacological studies have investigated potential dysfunction of neurotransmitters in migraine susceptibility. The involvement of serotonin in migraine has been known for many years following Sicu­teri’s observations of an increase of 5-hydroxyindoleacetic acid (5-HIAA), the main metabolite of serotonin, in the urine of 15 patients during migraine attacks [17]. This was the first indication of an anomaly of serotonin metabolism in migraineurs and since then, many scientific research studies have focused on the genetic components of the serotonergic system (see Table 1). Receptors, transporters and enzymes are the key molecular mediators that regulate and maintain serotonin levels in the brain and periphery. Serotonin is distributed in neuronal and several non-neuronal tissues of the cardiovascular system, gastrointestinal, renal systems and the blood [18]. Serotonin regulates a wide array of physiological functions via a specific set of receptors which are mostly G protein-coupled receptors (except receptor 5HT3 which is a ligand gated cation channel) that activate an intracellular second messenger cascade to mediate excitatory or inhibitory neurotransmission [19]. Serotonin receptors have been localized in vestibular and trigeminal ganglion cells in monkey [20].

Current research on the biology of the serotonergic system in disease is focusing on genetic alterations in synaptic and post-receptor signalling proteins that affect serotonergic neurotransmission by increasing or decreasing serotonin’s actual or effective availability in the CNS (See Table 1) [21]. Genetic variability at the level of gene transcription, mRNA processing and translation or post-translational modification as well as intracellular trafficking in the genetic components of the serotonergic system may generate gene products that may lead to structural and functional changes in brain circuits and provoke disease [22]. The two most studied components of the serotonergic system that have come into the spotlight in determining susceptibility to migraine as well as multiple neuropsychiatric disorders are the serotonin transporter (SERT, also known as SLC6A4), which reuptakes serotonin from the synapse, and monoamine oxidase A (MAOA), an important enzyme that degrades serotonin and metabolizes triptans [23]. Both these proteins are important in regulating levels of serotonin in the brain and carry polymorphisms in their promoter regions that cause differential transcriptional activity and thus impact drug metabolism [22, 24–26].

Several association studies have investigated genetic variants that may alter the functions of genes involved in serotonin functionality and regulation. The serotonin transporter gene *SERT* has been extensively studied. In this gene, two polymorphisms have been of particular interest. The first polymorphism consists of a 17 bp variable number of tandem repeats known as (STin2 VNTR)
**Table 1 Genetic components of the serotonergic system**

| Enzyme                              | Gene | Locus            | Function                                                                                   | Significance for migraine                             |
|-------------------------------------|------|------------------|--------------------------------------------------------------------------------------------|-------------------------------------------------------|
| Tryptophan hydroxylase 1           | TPH1 | 11p15.3-p14      | TPH1, peripheral form, converts tryptophan to 5 hydroxy tryptophan, rate-limiting step in the synthesis of 5-HT, determines the availability of 5-HT and its rate of production. | TPH enzymes regulate brain-specific serotonin deficiency, weak association [43]. |
| Tryptophan hydroxylase 2           | TPH2 | 12q21.1          | TPH2, neuronal form, synthesis of serotonin.                                                |                                                        |
| Monoamine oxidase A                | MAO-A| Xp11.3           | MAO-A, outer mitochondrial membrane, oxidative deamination of amines, such as dopamine, norepinephrine, and serotonin. | Enzymes metabolise triptans.                          |
| Monoamine oxidase B                | MAO-B| Xp11.23          | MAO-B, both subtypes have a widespread occurrence in the brain and in peripheral tissues. | MAO inhibitors promote the accumulation of monoamines and reduce uncontrolled vasodilation, and were used in treating migraine but discontinued due to side effects [73]. |
| Amino acid decarboxylase            | DDC  | 7p12.2           | DDC, catalyses the decarboxylation of L-5-hydroxytryptophan to 5-HT and L-tryptophan to tryptamine. |                                                        |
| Aldehyde dehydrogenase 2           | ALDH2| 12q24.2          | ALDH2, located in mitochondria produce 5-hydroxyindole acetic acid as the major excreted metabolite of serotonin. |                                                        |
| Receptor Protein                   |      |                  | Potential and mechanism                                                                      |                                                        |
| Serotonin 5HT1                     |      |                  | Significance for migraine                                                                    |                                                        |
| 5HT1                               | HTR1A| 5q11.2-q13       | Inhibitory, decreasing cellular levels of cAMP                                               | Co-localization of 5HT1B, 5HT1D, and HTR1F receptor subtypes in vestibular ganglia [20, 74]. Triptans have high affinity for serotonin receptors. |
|                                    | HTR1B| 6q13             |                                                                                             |                                                        |
|                                    | HTR1D| 1p36.3-p34.3     |                                                                                             |                                                        |
|                                    | HTR1E| 6q14-q15         |                                                                                             |                                                        |
|                                    | HTR1F| 3p12             |                                                                                             |                                                        |
| Serotonin 5HT2                     |      |                  | Significance for migraine                                                                    |                                                        |
| 5HT2                               | HTR2A| 13q14-q21        | Excitatory, increasing cellular levels of IP3 and DAG                                         | Cortical density of the excitatory 5-HT2 receptor, which is involved in pain processing, is not altered interictally in migraine patients [76]. |
|                                    | HTR2B| 2q36.3-q37.1     |                                                                                             |                                                        |
|                                    | HTR2C| Xq24             |                                                                                             |                                                        |
| Serotonin 5HT3                     |      |                  | Significance for migraine                                                                    |                                                        |
| 5HT3                               | HTR3A| 11q23.1          | Excitatory, depolarizing plasma membrane                                                      | Role in facilitation of inflammatory and neuropathic pain [77]. |
|                                    | HTR3B| 11q23.1          |                                                                                             |                                                        |
|                                    | HTR3C| 3q27.1           |                                                                                             |                                                        |
|                                    | HTR3D| 3q27.1           |                                                                                             |                                                        |
|                                    | HTR3E| 3q27.1           |                                                                                             |                                                        |
| Serotonin 5HT4                     |      |                  | Significance for migraine                                                                    |                                                        |
| 5HT4                               | HTR4A| 5q31-q33         | Excitatory, increasing cellular levels of cAMP                                               | Central 5-HT4 receptor binding might serve as a biomarker of serotonergic tonus in the human brain [78]. |
Table 1 Genetic components of the serotonergic system (Continued)

| Transporter protein                  | Gene    | Locus   | Function                                  | Significance for migraine                                                                 |
|-------------------------------------|---------|---------|-------------------------------------------|------------------------------------------------------------------------------------------|
| Serotonin transporter, SERT         | SLC6A4  | 17q11.2 | Reuptakes serotonin from the synapse, role in psychiatric disease | Meta-analyses by the groups of Liu and Schurks report a positive association with SERT and migraine [27, 28]. |
| Plasma membrane monoamine transporter, PMAT | SLC629A4 | 7p22.1 | Transport of both serotonin and dopamine  |                                                                                           |

| 5HT 5-hydroxytryptamine, cAMP cyclic adenosine monophosphate, IP3 inositol trisphosphate, DAG diacylglycerol, SNP single nucleotide polymorphism |

Note: PMAT (Plasma membrane monoamine transporter) is involved in the transport of both serotonin and dopamine
in intron 2 with two common alleles (STin2.10 and STin2.12) composed of 10 or 12 repeat units respectively [27]. To get a clearer picture, Schurks et al., [27] considered five studies that evaluated the 5-HTT VNTR STin2 polymorphism and concluded the STin2 12/12 genotype may be influential in determining migraine susceptibility among populations of European descent. A further meta-analysis by Liu et al., [28] reviewed 15 studies and found that the 5-HTT VNTR STin2 12/12 genotype confers an increased risk for migraine in the general population.

The second polymorphism is a 44-bp insertion/deletion functional polymorphism in the promoter region known as 5-HTTLPR. There are two common allelic forms, and the 14 repeat containing short variant (S) is associated with slower clearing of serotonin from the synaptic cleft [29]. Analysis of this polymorphism has provided conflicting results. The S allele has shown association with migraine in some studies [30–33] while in other studies no evidence of association was identified [34, 35]. In a meta-analysis of 10 studies of Europeans and Asians Schurks et al., reported no overall association between the 5-HTTLPR polymorphism and migraine, although gender and migraine aura status may influence results among Europeans [29]. Although various polymorphisms in serotonin related genes have showed altered allelic distribution in different migraine populations there has been, to date, insufficient evidence to confirm a specific serotonin receptor gene being directly associated with the disorder [36, 37].

Genetic studies continue to provide new data regarding the involvement of serotonin in migraine and in particular support the idea that migraine is a polygenic disorder as recently reported in a large meta-analysis of 375,000 individuals by Gormley et al., [38] that identified 38 susceptibility loci for migraine. Thompson et al. identified a positive association at the 5-HT1D locus for migraine. Thompson et al. identified a positive association at the 5-HT1D locus for migraine. Jung et al., [43], did not find a positive association with migraine for two SNPs (rs1487275 and rs1386486) in the TPH2 gene (TPH1 is the peripheral form, TPH2 is the neuronal form) in a population of 503 migraineurs and 515 healthy controls [43]. Although this study does not support TPH2 as a key player in the migraine circuit TPH2 is emerging as a therapeutic target for stress disorders and abnormalities in TPH activity have been implicated in a variety of psychiatric disorders [44–46]. Conceivably, there may be other effects, including epigenetic, gene regulatory and or expression effects affecting this locus yet to be determined [44]. These data together with TPH2 knockout mice have provided additional insights into the role of TPH enzymes in regulating brain-specific serotonin deficiency [47–49].

**Migraine therapy and triptans**

Triptans are currently the most effective drugs in treating migraine and are the supporting pillar of migraine therapy [50]. Triptans amplify the serotonin signal by stimulating serotonin receptors located in cranial blood vessels and nerve endings and relieve pain by constricting blood vessels and inhibiting the release of peptides, including CGRP [51] and substance P as well as acting in other ways not yet known [52]. At the cellular level triptans alleviate migraine symptoms by binding to serotonin 5-HT1b, d and f receptors along pain signaling circuits and are effective due to high receptor specificity and disease specificity [53]. Recent studies [54–56] continue to reveal triptans complex actions including meta-analyses comparing the effectiveness of triptans alone or in combination with other drugs [57]. Although triptans are the most effective drugs for migraine they exhibit therapeutic variability in different patient groups. The different levels of drug response can be explained by different metabolic routes, rates and efficiency.

In a meta-analysis by Cameron et al., 133 randomized controlled trials were included and the conclusion from this study was that triptans are generally better than ergots and provide equal or better pain relief when compared with non-steroidal anti-inflammatory drugs (NSAIDs), acetysalicylic acid (ASA) and acetaminophen [57]. Triptans used in combination with ASA or acetaminophen, or by alternative administration methods (injectables) yielded slightly better outcomes than standard dose triptan tablets. Thorlund et al., evaluated the efficacy of seven triptans in a multiple treatment comparison meta-analysis by examining data from 74 double-blinded randomized clinical trials comparing triptans to either placebo or to another triptan [58]. Among the seven different triptans tested, eletriptan was the best triptan and all triptans were found better than placebo [58]. This result was also upheld by a recent
report showing that triptans still have the most favorable efficacy-tolerability profile [59].

The hunt for better more specific drugs continues particularly in the era of pharmacogenetic research whose goal is to evaluate the impact of genetic constitution on migraine drug response [60]. Pharmacogenetics recognizes that numerous genes (drug metabolizing enzymes and drug transporters) play a role in the mechanism of drug response, resistance, toxicity, drug transport or drug targeting and ultimately affect how patients metabolize and consequently respond to different drug regimens [61, 62]. This information can help inform doctors prescribing practices i.e. responders versus non-responders, avoiding adverse drug reactions, optimizing drug dose for the individual and ultimately guide prescription of the ‘right’ triptan to the ‘right’ patient [63].

In a study by Terazzino et al., the STin2 VNTR polymorphism in the SERT gene was shown to be associated with a higher risk of inconsistent response to triptans in migraine patients [64]. However the authors caution some limitations in their study such as a small sample size but nevertheless support future pharmacogenetic testing to identify algorithms for more effective treatment [64]. Recently, Christensen et al. identified a single risk variant, rs2651899 in the PRDM16 gene among 12 single nucleotide polymorphisms (SNPs) genotyped chosen based on prior GWAS findings by Antilla [65] to be significantly associated with efficacy of triptans [60]. To explore the role of genetic factors in drug metabolism Gentile et al., 2010 genotyped polymorphisms in CYP450 and MAOA, genes that are involved in Phase I metabolic reactions, and in target mechanisms (GNB3) of triptans and reported a significant correlation between MAOA uVNTR polymorphism and a chronic migraineous population [66, 67]. Serotonin receptors are also targeted by other drugs besides triptans and in a study by Brandl et al., polymorphisms in serotogenic genes (HTR2A, SERT) were found to be associated with anti-psychotic treatment response [68].

In addition to pharmacogenomics a new paradigm has emerged ‘pharmacometabolomics’ for characterizing the metabolic (pharmacokinetic and pharmacodynamic) response to a drug taking into account both environmental and genomic factors [69]. Although there is still a paucity of studies in this domain, recent studies are using both metabolomic and genomic data to study selective serotonin reuptake inhibitor (SSRI) treatment outcomes in patients with major depressive disorder (MDD) by use of a “pharmacometabolomic-informed” pharmacogenomic research strategy [70]. In a follow up study in 2016, Gupta et al., uncovered two main SNP signals in two candidate genes (TSPAN5 and ERICH3) which were associated with the clinical response to SSRI therapy in MDD patients [71]. Functional genomic studies assessed serotonin pathway enzyme expression after knockdown (KD) or over-expression (OE) of TSPAN5 and ERICH3 in neurally-derived cell lines by qRT-PCR and quantitative Western blot. KD of TSPAN5 was associated with a significant decrease of mRNA and protein levels for the serotonin pathway enzymes TPH1, TPH2, DDC, MAOA, as well as the serotonin transporter SLC6A4. Both TSPAN5 and ERICH3 proteins affect serotonin concentrations in cell culture media. The identification of ERICH3 and TSPAN5 in the regulation of serotonin or variation in SSRI response is novel and recent studies have reported TSPAN5 may also promote Notch signalling [72].

Although specific SNPs in genes that metabolize triptans have yet to be identified, current pharmacogenetics studies indicate that defining the effect SNPs have on drug metabolism and treatment response may have value in classifying patients into groups of poor metabolizers to predict therapeutic responses and to evaluate sex differences. Several studies have shown that SNPs in genes of most metabolic enzymes can affect enzyme activities and may account for inter-individual variation, in drug bioavailability and efficacy and consequently can bear a role in therapy response [63]. Results of future testing the clinical utility of SNPs and genetic variability in the signalling components of the serotonergic system as well as additional genes involved in triptan metabolism will impact patient care and may be useful to personalize medicine.

Metabolic routes of serotonin

Tryptophan - Indole-kynurenine-niacin pathway
Tryptophan is a requisite precursor necessary for various metabolic reactions primarily the synthesis of serotonin, proteins, melatonin, tryptamine and kynuramines [82, 83]. In the body, tryptophan is metabolized, via two basic pathways, the indole-kynurenine-niacin pathway and the serotonin-melatonin pathway [84]. The majority of tryptophan, 99% is metabolized and degraded along the kynurenine pathway which generates neuroactive compounds collectively called the kynurenines that antagonize the NMDA receptors [85]. Several studies of neurological diseases have reported kynurenine pathway (KP) metabolites and/or enzyme activity to be up- and/ or down-regulated in relation to disease [86, 87]. Recently Curto et al., identified an association of fluctuations of kynurenine metabolites in serum samples from 21 cluster headache patients [88]. Curto et al., also identified altered kynurenine pathway metabolites in serum of chronic migraine patients [89]. Indeed activation or inhibition of kynurenine pathway enzymes and accumulation of kynurenines within the CNS has been considered a therapeutic strategy [90]. However, the potential of this therapeutic strategy has not yet been tried in migraine [91].
To investigate central and peripheral serotonin turnover in neurological disorders and in depressed mood, researchers have adopted the tryptophan depletion technique (Acute Tryptophan Depletion ATD) [82]. Initial studies in healthy volunteers showed that depletion of tryptophan is correlated with a decline in central serotonin turnover [92, 93]. The tryptophan-serotonin relationship has been confirmed in animal models [94–96] and was first demonstrated in 1970, indicating this mechanism may be potentially important in serotonin related pathologies in humans [97, 98]. Changes in the composition of the blood plasma in the periphery can influence functioning of the nervous system and affect various serotonin-dependent brain functions and mood states like depression [99–101]. Changes in diet and nutrition can lead to changes in brain levels of the precursors for neurotransmitter synthesis and influence the rates at which neurons synthesize neurotransmitters [101]. Tryptophan depletion increases nausea, headache and photophobia in migraine sufferers [102]. Two studies in the 70s, tested L-tryptophan treatment in headache patients and reported headache indices were markedly lower with supplementation of L-tryptophan than with placebo [103, 104]. The utility of tryptophan for both research and clinical purposes has been underexplored. Further analysis of the relationship of plasma tryptophan with brain serotonin metabolism in both normal and diseased states will be beneficial to understanding the complex serotonergic biochemistry of migraine.

**Tryptophan - Serotonin-melatonin pathway** Melatonin is a hormone that is synthesised at night-time from the precursor tryptophan in the pineal gland. Endogenous melatonin plays an important function in regulating circadian rhythms for proper sleep-wake cycles as well as many neuronal and hormonal functions [105, 106]. Multiple studies have demonstrated altered levels of melatonin secretion at night in the plasma or urine of migraine patients with cluster headache, migraine with and without aura, menstrual migraine, and chronic migraine relative to controls that spurred further investigation of melatonin as a prophylactic therapy [107–113]. Melatonin has also been found to be altered in other central nervous system (CNS) disorders, such as stroke, obsessive-compulsive disorder, mood and schizophrenia [114, 115]. Melatonin has regulatory effects on gastrointestinal tract motility and sensation, has sleep promoting effects and mood regulation and anti-stress effects [116]. Consequently, it is not surprising that melatonin supplements have shown potential in diminishing pain intensity in migraine comorbid conditions such as fibromyalgia and irritable bowel syndrome [116, 117].

Melatonin has been considered to hold therapeutic properties on headache profiles due to its normalizing effects on circadian rhythms and sleep and was further pursued in controlled trials because it is non-toxic, low cost and easily available over the counter in most countries (see Table 2) [118, 119]. Bougea et al., [120] conducted the longest trial lasting for a period of 6 months and demonstrated a positive effect in a children patient group. Studies on melatonin use in migraine have had some limitations, such as lack of adequate control and placebo, had a small sample size and throughout some of the trials the patients were permitted to take rescue medication for symptomatic relief of migraine during the trial period, limiting the comparisons that can be made. The future of melatonin-based therapy may also include melatonin receptor agonists and the design of trials with a longer follow up period, standardized designs, controls and IHS guidelines to establish the utility of melatonin-based therapy as a prophylactic therapy [121].

**Tryptophan and tryptamine** Tryptamine is another functional neuromodulator produced from tryptophan metabolism and structurally related to serotonin [126, 127]. D’Andrea et al., [115] identified low levels of tryptamine in the plasma of 73 chronic migraine CM patients and 13 chronic tension-type headache (CTTH) patients relative to a group of 37 healthy subjects [128]. In contrast the levels of circulating 5-HT and 5-HIAA were within normal range. The low tryptamine plasma levels found in CM and CTTH patients lead the authors to the conclusion that these two primary chronic headaches are characterized by “neurotransmitter and neuromodulator metabolic abnormalities in a hyperexcitable and hypoen energetic brain” due to insufficient serotonergic control of the pain threshold [129]. The role of tryptophan and tyrosine metabolism in migraine headache is reviewed in D’Andrea et al., [129–131].

**PET imaging studies of serotonin** In the study of neurological disorders such as migraine, a recognizable limitation with investigating in vivo the biochemistry of CNS functioning is access to neuronal brain tissue of affected patients for controlled experimental study [132]. In view of the non-existence of high-quality post-mortem brain tissue samples to study CNS functioning in vivo, peripheral blood is being proposed as a valid surrogate for genetic studies of migraine [133], along with cerebrospinal fluid, saliva, platelets, plasma and urine to study neurotransmitter function. Given that migraine is a complex multi-faceted disorder, it makes sense to take a multi-dimensional approach that considers the whole organism.

The continued development and increasing availability of positron emission tomography (PET) and single positron emission computerized tomography (SPECT), and radio-ligands has enabled the study of serotonergic
| Reference          | Study design                                      | Cases and migraine type | Daily dose and duration                                                                 | Primary endpoint                                                                 | Result      |
|--------------------|---------------------------------------------------|--------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|-------------|
| Peres et al., 2004 [122] | open-labelled                                     | Total adults, 32         | 3 mg/day, 30 min before bedtime for 3 months                                            | Percentage of patients with >50% reduction in migraine frequency                | positive    |
| Miano et al., 2008 [123] | open-labelled                                     | Total children, 22       | 3 mg/day for 3 months                                                                  | Reduced the frequency of headache attacks by >50% from baseline                 | positive    |
| Alstadhaug et al., 2010 [124] | randomized, double-blind, placebo-controlled crossover study | Total adults, 46         | 2 mg/day prolonged release melatonin, given 1 h before bedtime for 2 months            | Migraine attack frequency (AF)                                                  | negative    |
| Fallah et al., 2015 [125]   | open-labelled, non-randomized, uncontrolled       | Total children, 60       | 0.3 mg/kg for 3 months                                                                 | Percentage of patients with >50% reduction in migraine frequency                | positive    |
| Bougea et al., 2016 [120]   | open-labelled                                     | Total children, 41       | 4 mg/day 30 min before bedtime for 6 months                                             | Reduced headache frequency                                                      | positive    |

CCH chronic cluster headache, ECH episodic chronic headache, TTH tension-type headache, CTTH chronic tension-type headache, MA migraine with aura, MO migraine without aura, M migraine
biology in vivo [134, 135]. Due to high sensitivity and better anatomic resolution, imaging techniques have provided an entry point to study perturbed functional networks in neurologic and psychiatric disorders [136] and obtain more information about the distribution, density and activity of single receptor molecules in relation to migraine-specific actions of triptans [137]. Three studies, have thus far employed the non-invasive method [138] PET imaging using the tracer α-[11C] methyl-L tryptophan (11C-AMT) for measuring serotonin synthesis in the human brain [139]. This method is based on the regional trapping of tracer 11C-AMT concentration and uses in vivo measurements of 11C-AMT plasma with reference to the brain trapping constant (K*, mL/g/minute) [138]. Using this method, Chugani et al., [127] reported a trend of elevated serotonin synthesis capacity in three female patients with MO after migraine patients were treated prophylactically with beta-adrenergic antagonists propranolol or nadolol, thought to be due to antagonism of the 5-HT1A receptor on serotonergic neurons [140]. Additionally, two other PET studies demonstrated that serotonin receptors/transporters can be upregulated interictally (in between attacks) in migraine [141, 142].

Sakai et al., performed a similar study in six migraine patients with PET imaging, scanning participants during an attack, after administering sumatriptan and in between attacks [143]. Statistically significant changes were reported only in the migraine group treated with sumatriptan. Serotonin synthesis was significantly reduced, with a 33% reduced uptake of 11C-AMT in a majority of brain regions, similar effects were also reported in rats [143, 144]. The observed decrease in serotonin synthesis could be the body’s physiological adaptation to the presence of triptan which mimics the effect of serotonin. In a recent study, Sakai et al. tested the hypothesis of serotonergic dysfunction in migraine by scanning six female migraine subjects with MO at baseline and after oral administration of 40 mg of eletriptan, the triptan with the highest lipophilicity [145]. In the migraine group who received eletriptan, a significantly reduced (16.3%) global K* value for serotonin was obtained in the migraine subjects in the interictal phase of their condition [145]. Park et al., in a pilot study of eight female migraine patients investigated the availability of SERT in the brain stem and concluded that migraineurs who experience more painful headaches have lower serotonin neurotransmission and additionally reported an age-related decline of SERT availability [146]. In summary, the results from these studies suggest that brain serotonin synthesis rate may be altered in migraineurs and that triptans are effective on pain pathways by decreasing brain serotonin synthesis.

Biochemical studies of serotonin in CSF and saliva

The underlying hypothesis motivating studies of CSF is that because CSF is in direct contact with the brain interstitial fluid, serotonin and biochemical changes in the brains of migraine patients may best be reflected in this fluid [147]. Studies examining CSF are few, however, because they require spinal puncture, a costly and invasive procedure. Two studies, measuring serotonin activity in CSF can be found, one by Barrie et al., [135] which indicated no change in 5HIAA levels in CSF of migraine patients with respect to the controls and [148] one study by Kangasni et al., [149] reported an increase in 5HIAA levels in CSF (see Table 4).

Saliva has been used as a diagnostic tool to evaluate neurotransmitter function because it contains a variety of neuropeptides, integrating with the trigeminovascular and neuroendocrine systems [150–152]. There have been more studies trying to use saliva in the diagnostic and therapeutic assessment of migraine, e.g. the studies of Cady et al. [153] and Bellamy et al. [154] on CGRP in saliva of migraineurs. To date only one study by Marukawa et al., reported higher concentrations of serotonin and substance P in TTH patients [155]. The clinical usefulness of saliva has not yet been established, additional studies may be able to develop protocols able to make use of this easily accessible fluid, perhaps through correct timing of sampling [156].

Biochemical studies of serotonin in platelets

Interest in investigating platelets and peripheral biochemical factors is based on their interaction and proximity with the vascular endothelium. The vascular endothelium is a metabolically and physiologically active tissue that is semi-permeable and is important in regulating vascular tone [157]. Neurotransmitters and other vasoactive agents capable of modulating the nerve and vascular systems are actively produced by the vascular endothelium and can disrupt endothelial function [158]. Complex functional interactions that cause changes in endothelial function, vascular oxidative stress, promote platelet activation and enhance the inflammatory process can change the coagulant properties of blood producing alterations in neurovascular function and platelets may be an important part of these processes [159–162]. Attention has turned to the role of platelets in migraine due to the association and comorbidity of migraine with several cerebrovascular disorders, including arterial dissection, ischemic stroke, and cardiovascular disease as well as the increased risk of thromboembolic events and the favourable effects of anti-platelet medication [163, 164].

Platelets carry the largest reserve of serotonin which they capture from enterochromaffin cells [165]. In the gastrointestinal tract, serotonin acts as a key signalling molecule mediating many GI functions, including peristalsis, secretion, vasodilation and perception of pain or nausea, vomiting, which are common symptoms experienced by migraineurs [166–168]. Additionally, platelets...
express SERT proteins (membrane-bound serotonin-selective reuptake transporter) that are identical to brain SERT [169]. Due to its role in clearing serotonin from the synaptic cleft, SERT plays a central role in neurotransmission and a broad role in brain activity making it a sought after therapeutic target of multiple neuropsychiatric disorders [170]. SERT knockout mice display notable reduction (60–80%) in serotonin concentration in several brain regions [171] and markedly depletes serotonin tissue stores [172–174].

Numerous studies have found an association between migraine and a dysfunction in platelets (see Tables 3 and 4). The platelet changes that have been described in migraineurs include increased platelet-to-platelet aggregation and up-regulation of platelet-leukocyte aggregates. Morphological differences in platelets of migraineurs reported include: 1) containing more ADP; 2) having more dense granules and; 3) showing qualitative differences in their serotonin release reaction and clumping [175]. The contemporary literature is not conclusive on the relationship between platelet serotonin content and migraine however it generally agrees that the distorted behaviour of platelets presents with subtle changes in various functions (reviewed in [176]). In a case study of two sisters with hemiplegic migraine, low levels of systemic serotonin, including the CSF serotonin metabolite 5-hydroxyindoleacetic acid and low platelet serotonin levels were described [177]. Interestingly, administration of 5-hydroxytryptophan (a precursor of serotonin) and carbidopa ameliorated the sisters’ clinical symptoms.

For the most part, investigations report increased platelet activation and it is argued that these changes could reflect parallel biochemical changes in the CNS (see Tables 3 and 4). Patterns of platelet behaviour/activation have also been found to differ in migraine subgroups, a finding that could indicate different pathological mechanisms [178, 179]. There is, however, no platelet phenotype that can be used as a direct diagnostic biomarker for migraine [180]. It is difficult to draw final conclusions for platelet biology studies in migraine as they have investigated different aspects of platelet biology and have at times reported contrasting results. The general state of affairs is that platelet anomalies are not considered to be causal for migraine and that this topic merits additional investigation to gain a fuller understanding [181].

**Biochemical studies of serotonin in plasma**

Data regarding serotonin levels in plasma of migraineurs should be treated with caution due to differing definitions of plasma serotonin and determination of serotonin content in plasma. This is because normal blood plasma is composed of two distinguishable fractions namely platelet-rich-plasma (PRP) and platelet-poor plasma (PPP) [182]. Platelet-rich-plasma is blood plasma that is mostly bound to platelets whereas platelet-poor plasma refers to the fraction of freely circulating serotonin which is said to be distinct to PRP. This fraction of blood plasma contains a very low number of platelets and is identified as the extraplatelet pool [183]. This portion of plasma is difficult to assay consistently owing to the difficulty of preparing PPP without causing release of serotonin from platelets and without platelet contamination. Additionally, whether or not a study is using PPP or a less refined plasma subset is often unclear, adding to uncertainty [183]. This is perhaps demonstrated in the contrasting results that have been obtained with a few studies reporting elevated levels of plasma serotonin, specifically studies by Dvilansky et al., 1976, Ferrari et al., 1989 and Milovanovic et al., 1999 [184–186] (see Tables 3 and 4). Conversely studies by Curran et al., [187], Rydzewski, [188] and Nagata et al., [189] reported lower levels of plasma serotonin in migraineurs than in controls during the attack. More consistency and standardised methods of assaying blood plasma in biochemical studies are required in order to move forward.

**Biochemical studies of serotonin in urine**

In addition to the studies examining serotonin metabolism in CSF, saliva, platelets and plasma there have been several studies using urine as a proxy for serotonin activity in the brain. These were often the first studies and were fundamental in highlighting a possible serotonin-dependent mechanism urging further investigation [17]. Four out of seven independent studies observed an increase in the urinary excretion of the main metabolite of serotonin, 5-hydroxyindoleacetic acid (5-HIAA), in association with migraine attacks [17, 149, 190, 177] (see Table 5). Two studies [186, 191] reported a decrease in urinary excretion of 5-HIAA and one study reported no difference [192]. Bousser et al., [191] provided evidence of a 31% lowered urinary 5-HIAA excretion in 44 young adult female migraine patients between attacks and in 33 healthy age- and sex-matched control subjects [191]. Milovanovic et al., [173] reported a similar trend of lowered urinary 5-HIAA excretion although the sample size in this study was smaller consisting of a total of 18 migraine patients [186]. Despite urine’s ease of access, only a small number of studies have thus far investigated the biochemistry of urine in migraineurs.

**Biochemical model of serotonin**

The existing data support the premise that serotonin is low interictally but increased ictally (during attacks themselves) in the migraine brain [143, 196]. According to this model, during an attack serotonin is released from platelets into blood plasma causing a short-lived increase in free plasma serotonin that raises serotonin
| Reference                        | Substance | Material and methods                                                                 | Cases/ Controls | Results                                                                 |
|---------------------------------|-----------|----------------------------------------------------------------------------------------|-----------------|------------------------------------------------------------------------|
| (Dalsgaard-Nielsen et al., 1974) | 5-HT      | 5-HT in platelets estimated by Udenfriends method                                       | M = 8, NC = 10 | No change in the uptake or the endogenous release of 5-HT               |
| (Kalendovsky, 1975)             | 5-HT      | Platelets from whole venous blood                                                      | M = 19, NC = 23 | Migraine patients demonstrate platelet hyperaggregability more than normal subjects to all aggregating agents tested | |
| (Dvilansky et al, 1976)         | 5-HT      | Platelets                                                                               | MO = 22, MA = 16| Plasma during attacks released significantly more 5-HT                 |
| (Muck-Seler et al, 1979)        | 5-HT      | Platelet poor-plasma (PPP) using spectrophotofluorimetric method of Crawford and Rudd   | M = 24, NC = 25 | Unchanged 5-HT platelet level during migraine attack                   |
| (Rolf et al, 1981)              | 5-HT      | Platelets                                                                               | MO = 23, MA = 10| ↓ 5-HT observed in patients with muscle contraction headache          |
| (Carroll et al, 1982)           | 5-HT      | Platelets                                                                               | MO = 25, NC = 18| ↓ reduced transport of 5-HT in platelets                              |
| (Oxman et al, 1982)             | 5-HT      | Platelets                                                                               | M = 16, NC = 10 | Membrane lipid composition may play a role in disease                 |
| (Lauray et al, 1982)            | 5-HT      | Platelets                                                                               | MO = 11, NC = 15| ↓ Kinetic factor $V_{max}$ and $K_{m}$ PRP 5-HT levels                |
| (Pradalier et al, 1983)         | 5-HT      | Platelets                                                                               | MO = 19, NC = 15| Unconjugated serotonin concentration was decreased during the attacks and decrease in 5-HT uptake by platelets, with a fall in $K_m$ and $V_{max}$ |
| (Kruglak et al, 1984)           | 5-HT      | Platelets                                                                               | M = 18, NC = 26 | Increased aggregability during attacks                                |
| (Lechner et al, 1985)           | 5-HT      | Optical density method                                                                  | M = 14, NC = 30 | ↑ enhanced platelet aggregation and platelet sensitivity in migraine patients |
| (Lingjaerde, 1986)              | 5-HT      | Platelets in platelet rich-plasma (PRP). This method measures $K_m$ and $V_{max}$       | MO = 14, MA = 10| The size of the granular compartment was larger for classic than for common migraine, and the efflux rate from compartment III was |
| (Shukla et al, 1987)            | 5-HT      | Platelets                                                                               | TTH = 20, M = 19, NC = 15 | ↑ uptake of 5-HT in platelets                                     |
| (Kozubski et al, 1987)          | 5-HT      | Platelets                                                                               | M = 12, NC = 10 | ↑ Increased number and affinity of fibrinogen receptors on the platelet surface in migraineurs. |
| (Joseph et al, 1988)            | 5-HT      | Plasma                                                                                  | MO = 7, MA = 5, NC = 6 | Abnormal sensitivity to PAF                                          |
| (D’Andrea et al, 1989a)         | 5-HT      | Platelets obtained from PRP from whole blood HPLC colourimetric detection               | MO = 19, MA = 9, NC = 15 | High NE levels and low 5-HT/NE ratio in platelets of patients with MA platelet dense body hyposecretion |
| (D’Andrea et al, 1989b)         | 5-HT      | Platelets                                                                               | MO = 19, MA = 9, NC = 15 | Adhesion, surface activation, aggregation were investigated. Platelet dense bodies were increased. Increase in the content of serotonin, not evident in MA |
| Study             | 5-HT | Measurement                                                                                   | M  | NC  | Notes                                                                                      |
|-------------------|------|-----------------------------------------------------------------------------------------------|----|-----|-------------------------------------------------------------------------------------------|
| (Herman et al., 1989) [226] | 5-HT | Platelet aggregation was monitored using PRP, in a computerized four-channel aggregometer (CARAT) | 10 | 9   | PAF may be involved in the pathogenesis of migraine and suggest that specific PAF receptor antagonists or synthesis blockers may help in the therapy of this disease |
| (Takeshima et al., 1989) [227] | 5-HT | Cold pressor test. Blood was sampled three times through the three-way cock before the stimulus, 1 min after the start of the stimulus, and 5 min after the start of the stimulus | 15 | 13  | Both PF4 and NE increased significantly, whereas FFA showed no remarkable changes. The increase of PF4, however, was independent of NE increase and FFA changes |
| (Riddle et al., 1989) [228] | 5-HT | Electron microscope                                                                          | 21 | 15  | Demonstrated structural alterations and increase in the number of dense bodies               |
| (Kovacs et al., 1990) [179] | 5-HT | Platelets in platelet rich-plasma (PRP)                                                        | 17 | 14  | Migraineurs have altered platelet aggregation properties and PAF may play a role. The EC50 value for ADP and platelet-activating factor were significantly higher. |
| (Govitrapong et al., 1992) [229] | 5-HT | Platelets                                                                                     | 12 | 12  | Migraine have decreased membrane fluidity                                                   |
| (Jensen, 1994) [231] | 5-HT | Platelet membrane fluidity was measured using the fluorescent probe TMA-DPH                   | 11 | 17  | Increased 5HT during attacks                                                                 |
| (Kitano et al., 1994) [232] | 5-HT | Platelets                                                                                     | 19 | 10  | ↑ in the maximal number of receptors (Bmax) on platelet membrane of migraine patients when compared to the normal healthy group |
| (Jarman et al., 1996) [233] | 5-HT | Platelets \[14C\]5HT release measured by Lingjaerde and Monstad method                         | 8  | 10  | No change in release of platelet 5-HT                                                       |
| (Fioroni et al., 1996) [234] | 5-HT, 5-HIAA, MAO-B | Platelets                                                                                     | 7  | 8   | ↓ reduced 5-HT and ↑ increased 5HIAA in luteal phase, suggesting a greater susceptibility   |
| (Srikiatkhachorn, 1996) [235] | 5-HT | Platelets in platelet rich-plasma (PRP)                                                        | 20 | 20  | ↓ Kinetic factor Vmax and Kcat uptake of 5-HT                                               |
| (Pukhal'skaya et al., 1998) [236] | 5-HT | Platelets in platelet rich-plasma (PRP)                                                        | 8  | 8   | 5-HT transport systems in migraine patients and healthy donors are different                |
| (Oishi, 1998) [237] | 5-HT | Platelets                                                                                     | 10 | 10  | ↑ platelet factor A, D-thromboglobulin, thromboxane B, and 1-dehydrothromboxane B, concentrations in the plasma were significantly higher in the episodic tension-type headache group |
| (Srikiatkhachorn, 1998) [238] | 5-HT | Platelets                                                                                     | 10 | 10  | Excessive use of analgesics depletes 5-HT from its storage sites and results in the hyposerotonergic state. |
| Reference                  | Method                              | Results                                                                                                                                   |
|----------------------------|-------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| (Barchielli et al., 2004) [239] | 5-HT - Platelet-activating factor (PAF) HPLC radioimmunoassay method, internal jugular venous blood | MO = 5, ↑ production of PAF levels no change in activity of PAF acetyl-hydrolase (PAF-AH), enzyme involved in the catabolism of this phospholipid mediator, in migraine attacks |
| (Yucel et al., 2014) [240]   | 5-HT - Blood fibrinogen, D-dimer, galectin-3 determined by ELISA | M = 59, NC = 30, ↑ levels of fibrinogen, D-dimer, galectin-3 in migraine patients, ↑ higher D-dimer levels during migraine attacks may indicate hypercoagulability |

AAG Analgesic Abuse Group, CDH chronic daily headache, CH Cluster headache, CM Complicated migraine, CMF Chronic migraine with fibromyalgia, MA Migraine with aura, MO Migraine without aura, NC normal control, PAF platelet-activating factor, PPP platelet-poor plasma, PRP platelet-rich plasma, TH Tension headache; ↑ Increase; ↓ Decrease; = Unchanged
| Reference                     | Substance | Material and methods                                                                 | Cases/ controls | Results                                                                 |
|------------------------------|-----------|---------------------------------------------------------------------------------------|-----------------|-------------------------------------------------------------------------|
| (Couch, 1976) [241]          | 5-HT      | Platelet aggregation was tested to 1.7uM adenosine diphosphate employing light transmission methods modified after Born | M = 33          | ↑ platelet aggregability was measured by a) grading aggregation curves and b) by measuring percent disaggregation 3 min after peak aggregation was less |
| (Couch, 1977) [242]          | 5-HT      | Platelets, optical density methods                                                      | M = 46          | ↑ migraine patients demonstrate platelet hyperaggregability, lower threshold for the platelet-release reaction and increased platelet stickiness following aggregation |
| (Deshmuck, 1977) [243]       | 5-HT      | Platelets                                                                              | M = 27          | Platelet adhesiveness to glass beads and platelet aggregation response to ADP, epinephrine, thrombin and serotonin increased during the prodrome phase of migraine |
| (Manotti et al., 1983) [244] | 5-HT      | ADP induced platelet aggregation, ADP threshold concentration, platelet malondialdehyde production stimulated by thrombin, Beta-Thromboglobulin level in PPP | M = 30          |                                                                 |
| (Waldenlind et al, 1985) [245]| Platelets | Platelets                                                                              | CH = 33         | ↓ Kinetic factor $V_{max}$ and $K_{m}$ = uptake of 5-HT |
Table 4 Selected large scale biochemical studies of platelet serotonin in migraine patients and controls (Continued)

| Study                          | 5-HT                  | Platelet membrane Na+/K+ --ATPase activity and fluidity were determined with the fluorescent probes TMA-DPH and DPH | MO patients↑ numbers of platelet-leucocyte aggregation and activation-dependent epitope expression
|--------------------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| Taffi et al., 2005 [255]       | MO = 57 NC = 35       | Migraine patients show intercritic changes in platelet membrane fluidity and activity that may be related to the oxidative stress caused by increased ONOO– levels |
| Yucel et al., 2014 [240]       | M = 59 NC = 30        | ↑ levels of fibrinogen, D-dimer, galectin-3 in migraine patients                                               |
|                               |                       | ↑ higher D-dimer levels during migraine attacks may indicate hypercoagulability                              |

CH cluster headache, CM complicated migraine, MA migraine with aura, MM menstrual migraine, MO migraine without aura, PPP platelet-poor plasma, PRP platelet-rich plasma, TH Tension headache, NC normal control; ↑ Increase; ↓ Decrease; = Unchanged
levels in the brain [197]. The second arm of the model posits that raised levels of serotonin in the brain, during a migraine attack, exerts a vasoconstrictor effect on intracerebral arteries initiating the aura phase and cerebral ischemia with resulting visual disturbances. The concentration of serotonin eventually lowers because serotonin is broken down and excreted and this lowering post-attack is thought to produce vasodilation of extracerebral arteries causing headache and pain [197]. Migraine is generally regarded as a low serotonin syndrome. Diminished levels of serotonin in the brain lower the threshold for pain and are evident in some disorders co-morbid with migraine including chronic tension headache [198] and depression [199] as well as other chronic diseases such as fibromyalgia, irritable bowel syndrome [200], premenstrual dysphoric disorder and depression. In addition, tricyclic antidepressants can also reduce the frequency of migraine attacks by increasing serotonin signalling further supporting a role for serotonin in the pathobiology of migraine [201]. Serotonin has also been implicated in CSD and the trigeminovascular pathway. Experimental depletion of serotonin in rats, enhances the development of CSD with accompanying cerebrovascular changes and increases responsiveness and sensitivity of the trigeminal system [202–204].

Metabolomics is an emerging field that has recently shown that variations in brain metabolic homeostasis are associated with neurological disorders [205, 206]. In particular a recent study by Shyti et al., [191] identified metabolic changes by mass spectrometry in a transgenic mouse model of hemiplegic migraine after experimentally induced CSD [207]. This is the first study demonstrating CSD-induced metabolite differences in Familial Hemiplegic Migraine type 1 R192Q mice relative to WT mice and that these events can be captured beyond the CNS in plasma samples. Although we still do not know what the connection of central and peripheral serotonergic changes in migraine may be, further study based on metabolic profiling of biological fluids which contain the “products of numerous genome-wide and proteome-wide interactions” [208], the ‘metabolome’ [209] will continue to shed light on the inner workings of the migraine brain. To study serotonin deficiency-associated mechanisms a study by Weng et al., used a metabolomics approach to identify biomarkers from serotonin deficient mice [47]. The mice were depleted of serotonin via two approaches (1) use of p-chlorophenylalanine (pCPA) to pharmacologically inhibit tryptophan hydroxylase (Tph), a rate-limiting enzyme in serotonin biosynthesis and (2) genetic knockout of the Tph2 isoform. In this study serotonin deficiency was associated with altered energy metabolism and several biomarkers were identified in the serotonin deficient mice to be significantly altered compared with the control mice [47]. Moreover, the combination of sensitive brain imaging techniques and metabolomics platforms hold optimism to identify novel metabolite-gene relationships and new insight into small molecular changes in neuronal metabolism to enhance our understanding of biochemical pathways “functional readout”. Pharmacometabolomics-informed pharmacogenomics studies will therefore occupy an important position in the coming tide of molecular and “omics” research.

| Table 5 | Biochemical studies of 5-hydroxyindoleacetic acid (5-HIAA) in the urine of migraine patients and controls |
|---------|---------------------------------------------------------------------------------|
| Reference | Migraine classification | Controls/cases | Sample tested | Levels | Controls/cases | Sample tested | Levels |
| (Sicuteri et al., 1961) [17] | Not reported | Controls: 15 | Urine | ↑ | Controls: 15 | Urine | ↑ |
| (Curran et al., 1965) [187] | Not reported | Controls: 10 | Urine | ↑ | Controls: 11 | Plasma | ↓ |
| (Curzon et al., 1966) [149] | Not reported | Controls: 4 | Urine | = | Controls: 6 | CSF | = |
| (Kangasni et al., 1972) [149] | Not reported | Controls: 6 | Urine | ↑ | Controls: 14 | M: 14 | ↑ |
| (Deanovic et al., 1975) [190] | (Headache, 1962) [193] | Controls: 4 | Urine | ↑ | Controls: 14 | M: 14 | ↑ |
| (Bousser et al., 1986) [191] | (Headache, 1970) [194] | Controls: 33 | Urine | ↓ | Controls: 5 | Plasma | ↑ |
| (Milovanovic et al., 1999) [186] | (ICHD-I, 1988) [195] | Controls: 11 | Urine | ↓ | Controls: 7 | TTH: 7 | ↓ |

M migraine, CSF cerebrospinal fluid, TTH Tension-Type Headache; ↑ Increase; ↓ Decrease; = Unchanged
Conclusion
The evidence so far points to migraine as a biochemically complex disorder involving several neurotransmitter systems which converge in their synaptic pathways. The general trend observed is that migraine patients have alterations of neurotransmitters in biological fluids with different biochemistry from controls, however the interpretation of the biological significance of these peripheral changes is unresolved. At present, despite the observation of biochemical alterations, specific diagnostic markers are lacking for this disorder. In addition MA and MO sufferers may exhibit varying degrees and types of neurotransmitter dysfunction due to differing neurological features of both migraine types which may be related to the aetiology and underlying genetic component of each migraine subtype. Insufficient serotonergic input due to changes in synthesis, release, receptor function/ expression, reuptake and transport in the brain and throughout the body may contribute to vulnerability to migraine. Genetic studies have highlighted involvement of the serotonin transporter gene SERT in migraine susceptibility. However, serotonergic biochemistry is complex and evidently a multiplicity of factors, rather than any single one, combine to result in migraine phenotypes. More research is required to shed light on the course of these various biochemical phenomena and enable more robust conclusions on causal relationships. The absence of modern biochemical studies underscores the need for more rigorously conducted research utilizing larger sample sizes, updated IHS classification criteria and more sensitive bioassays and instruments and standardized methods for sample collection, preparation/analysis. Novel approaches for investigating the serotonergic system using PET imaging technology integrated with a metabolomics and systems biology platform may help to better understand the biochemical milieu and metabolome of migraineurs and establish if the biochemical changes are linked to the clinical presentation of the disease process. In conclusion, given the therapeutic efficacy of triptans, investigating the functionality of the serotonergic system in the migraine brain remains on the agenda to illuminate disease pathmechanisms and new lines of treatment to enable a superior understanding of the disease process that will further aid in the diagnosis, treatment and management of migraine and headache related disorders.

Abbreviations
5-HIAA: 5-hydroxyindoleacetic acid; AAG: Analgesic abuse group; CDH: Chronic daily headache; CH: Cluster headache; CM: Complicated migraine; CMF: Chronic migraine with fibromyalgia; CD: Cortical spreading depression; CSF: Cerebrospinal fluid; MA: Migraine with aura; MW: Menstrual migraine; MO: Migraine without aura; NC: Normal control; PPP: Platelet-poor plasma; PRP: Platelet-rich plasma; TH: Tension headache

Acknowledgements
Claudia Gasparini was the recipient of a Griffith University Postgraduate scholarship. We dedicate this review to pay tribute to Federigo Sicuteri for his seminal contribution to migraine research.

Authors’ contributions
CG conceived and designed the review, drafted the manuscript and revised it for intellectual content. RS and LG revised the manuscript for intellectual content and provided essential comments to finalize the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Author details
1 Menzies Health Institute Queensland, Griffith University Gold Coast, Parklands Drive, Southport, QLD 4222, Australia. 2 Genomics Research Centre, Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Queensland University of Technology, Muske Grove, Kelvin Grove, QLD 4059, Australia.

Received: 11 October 2016 Accepted: 9 December 2016
Published online: 13 February 2017

References
1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboryans V, Abraham J, Ackerman I, Aggarwal R, Ahn SY, Ali MK, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Bahalim AN, Barker-Collo S, Barrero LH, Bartels DH, Basanez MG, Baxter A, Bell ML, Benjamin EJ, Bennett D, Bernabe E, Bhalla K, Bhandari B, Bikbov B, Bin Abdulhak A, Birbeck G, Black JA, Blencowe H, Blore JD, Blyth F, Bolliger I, Bonaventure A, Boulos S, Bourne R, Boussinesq M, Braithwaite T, Brayne C, Bridgett L, Brooker S, Brooks P, Brughua TS, Byam-Hancock C, Bucello C, Buchbinder R, Buckle G, Budke CM, Burch M, Burney P, Burstein R, Galabria B, Campbell B, Canter CE, Carabin H, Carapetsis J, Cartmela L, Cella C, Charlson F, Chen H, Cheng AT, Chou D, Chugh SS, Coflegg LE, Colan SD, Colquhon S, Colson KE, Condon J, Connor MD, Cooper LT, Corrieme R, Courtinovis M, de Vaccaro KC, Couser W, Cowle BC, Criqui MH, Cross M, Dabhariak KC, Daihiya M, Dahodwala N, Danserey D, Jany D, Davis A, De Leo D, Degenhardt L, Delivelleva R, Delossantos A, Dennenberg J, Derrett S, Des Jarlais DC, Dharmaratne SD, Dherani M, Diaz-Torne C, Dolk H, Dorsey ER, Driscoll T, Duber H, Ebel E, Edmond X, Elbazz A, Ali SE, Enkii H, Enwin PJ, Espindola P, Ewoigbokhan SE, Fazadlar F, Felgin V, Fenston DT, Ferrari A, Ferri CP, Fievre EM, Finucane MM, Flaxman S, Flood L, Foreman K, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabbe B, Gabriel SE, Gakidou E, Garatalla HA, Garcia B, Gaspari F, Gillum RF, Green G, Gosselin R, Grainger R, Groeger J, Guilemin F, Gunnell D, Gupta R, Haagsma J, Hagan H, Halasa YA, Hall W, Haring D, Haro JM, Harrison JE, Havmoeller R, Hay RJ, Higashi H, Hill C, Hoen B, Hoffman H, Hotz PJ, Hoy D, Huang JJ, Ibeanusi SE, Jacobsen KH, James SL, Jarvis D, Jasrasaria R, Jayaraman S, Johns N, Jonas JB, Karthikeyan G, Kassebaum N, Kawakami N, Keren A, Khoo JP, King CH, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurti R, LaRocca R, Laskett LL, Lathlean T, Leasher JL, Lee YY, Leigh J, Lim SS, Limb E, Lin JK, Lipnick M, Lipshtuhl SE, Liu W, Loane M, Ohno SL, Ologo RH, Oros R, Mabwejani J, MacIntyre MF, Malekzadeh R, Mallinger L, Manivannan S, Marcenes W, March L, Margolis DJ, Marks GB, Marks R, Matsuzuma T, Mozaffarian D, Mozaffarian D, Mozaffarian M, Mundt A, Narayan KM, Nelson P, Nevett MC, Newton CR, Noit S, Norman P, O’Donnell M, O’Hanlon S, Olives C, Omer SB, Ortland K, Osborne R, Ozgediz D, Page A, Palhni B, Pandian JD, Rivero AP, Patterson SB, Pearce N,
20. Usman HO, Balaban CD (2016) Distribution of 5-HT1F Receptors in Monkey Vestibular and Trigeminal Ganglion Cells. Frontiers in Neurology 7 (173). doi:10.3389/fneur.2016.00173

21. Booo J, Tremblay RE, Szyf M, Benkelfat C (2015) Genetic and early environmental influences on the serotonin system: consequences for brain development and risk for psychopathology. J Psychiatry Neurosci 40(1):15–18. doi:10.3138/jpn.140099

22. Lesch KP, Heils A (2000) Serotonergic gene transcriptional control regions: targets for antidepressant drug development? Int J neuropsychopharmacol 3(1):67–79. doi:10.1017/s1461458400001747

23. Nordquist N, Orelad L (2010) Serotonin, genetic variability, behaviour, and psychiatric disorders—a review. Ups J Med Sci 115(1):1–10. doi:10.3109/00207454.2010.557324

24. Collar DA, Stober G, Li T, Heili A, Catalano M, Di Bella D, Arranz MJ, Murray RM, Vallada HF, Bengal D, Muller CR, Roberts GW, Smralsidi E, Kirov G, Sharr P, Lesch KP (1996) A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry 1(6):453–460

25. Heils A, Teufel A, Petri S, Stober G, Riedeck P, Bengil D, Lesch KP (1996) Allelic variation of human serotonin transporter gene expression. J Neurochem 66(6):2621–2624

26. Sabol SZ, Hu S, Hamer D (1998) A functional polymorphism in the monoamine oxidase gene promoter. Hum Genet 103(3):273–279

27. Schurks M, Rist PM, Kurth T (2010) STin2 VNTR polymorphism in the serotonin transporter gene and migraine: pooled and meta-analyses. J Headache Pain 11(4):317–326. doi:10.1007/s10194-010-0230-3

28. Liu H, Liu M, Wang Y, Wang XM, Qiu Y, Long JF, Zhang SP (2011) Association of 5-HT gene polymorphisms with migraine: a systematic review and meta-analysis. J Neurol Sci 305(1–2):57–66. doi:10.1016/j.jns.2011.03.016

29. Schurks M, Rist PM, Kurth T (2010) 5-HTTLPR polymorphism in the serotonin transporter gene and migraine: a systematic review and meta-analysis. Cephalalgia 30(9):678–694. doi:10.1111/j.1468-2984.2010.01845.x

30. Yilmaz M, Erdal ME, Herken H, Cataloluk O, Barlas O, Bayazit YA (2001) Significance of serotonin transporter gene polymorphism in migraine. J Neurol Sci 185(1):21–27.

31. Juhász G, Zsombock L, Lázsa A, Gonda X, Sotonyi P, Faludi G, Bágdy G (2003) Association analysis of 5-HTTLPR variants, 5-HT2A receptor gene 102 T/C polymorphism and migraine. J Neurogenet 17(2–3):231–240

32. Borroni B, Brambilla C, Liberini P, Rao R, Archetti S, Gippioni S, Volta GD, Padovani A (2005) Functional serotonin-5-HTTLPR polymorphism is a risk factor for migraine with aura. J Headache Pain 6(4):182–184. doi:10.1007/s10194-005-0179-9

33. Marzina M, Messner R, Schmitt A, Lesch KP, Sommer C (2005) A functional serotonin transporter gene polymorphism is associated with migraine aura. Neurology 64(1):157–163. doi:10.1212/01.wnl.0000148597.52312.9E

34. Todt U, Freudenberg J, Goebel I, Heizner A, Heinez-Kuhn K, Rietschel M, Gobel H, Kubisch C (2006) Variation of the serotonin transporter gene SL-C4A4 in the susceptibility to migraine with aura. Neurology 67(9):1707–1709. doi:10.1212/01.wnl.0000242983.96222.93

35. Corinonas R, Sobido MJ, Rubias M, Cuenca-Leon E, Blanco-Arias P, Narberhaus B, Roig M, Leira A, Lopez-Gonzalez J, Macaya A, Comard B (2010) Association study of the serotoninergic system in migraine in the Spanish population. Am J Med Genet B Neuropsychiatr Genet 153B(1):176–183. doi:10.1002/ajmg.b.30972

36. Ogilvie AD, Russell MB, Dhall P, Battersby S, Ulrich V, Smith CA, Goodwin GM, Harmar AJ, Olesen J (1998) Altered allelic distributions of the serotonin transporter gene in migraine without aura and migraine with aura. Cephalalgia 18(1):1–6.
Gobel H, Esserlind AL, Christensen AF, Hansen TF, Werge T, Kaprio J, Aromaa AJ, Raiatka O, Iikam MA, Spector T, Jarvelin MR, Metspalu A, Kubisch C, Strachan DP, Ferrari MD, Bellin AC, Dichtmans M, Wessman M, van den Maagdenberg AM, Zwart JA, Boomsma DI, Smith GD, Stefansson K, Erikkson N, Daly MJ, Neale BM, Olsen J, Chasman DI, Nyholt DR, Palotie A (2016) Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat Genet 48(8):856–866. doi:10.1038/ng.3598

Thurmond K, Mills EL, Wu P, Ramos E, Chatterjee A, Drury P, Goadsby PJ (2014) Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis. Cephalalgia 34(4): 258–267. doi:10.1177/0333102413480861

Hougaard A, Teelt-Hansen P (2015) Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists. Expert Opin Drug Metab Toxicol 11(9):1469–1418. doi:10.1517/17425255.2015.105244

Christensen AF, Esserlind AL, Werge T, Stefansson H, Stefansson K, Olsen J (2015) The influence of genetic constitution on migraine drug responses. Cephalalgia 35(11):1539–1550. doi:10.1177/0333102414545388

Gentile G, Chiassi L, Lionetto L, Martelletti P, Borro M (2014) Pharmacogenetic insights into migraine treatment in children. Pharmacogenomics 15(11):1539–1550. doi:10.2217/pgs.14.104

Buzzi MG (2008) Pathways to the best fit of triptans for migraine patients. Cephalalgia 28(Suppl 1):21–27. doi:10.1111/j.1468-2982.2008.01687.x

Gentile G, Borro M, Sirmmaco M, Missori S, Lala N, Martelletti P (2011) Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy. Expert Opin Drug Metabol Toxicol 7(1):39–47. doi:10.1517/17425255.2011.358680

Terrazzino S, Viana M, Floriddia E, Monaco F, Mattino D, Sances G, Tassorelli C, Nappi G, Rinaldi M, Canonico PL, Genazzani AA (2010) The serotonin transporter gene polymorphism SERTVNTR confers an increased risk of inconsistent response to triptans in migraine patients. Eur J Pharmacol 641(1-2):38–47. doi:10.1016/j.ejphar.2009.04.049

Anitila V, Winnows BD, Gormley P, Kurth T, Bertelli F, Mcmahon G, Kallela M, Malik R, de Vries B, Terwindt G, Medland SE, Todt J, McDade WL, Quaye L, Koiranen M, Iikam MA, Lehtimaki T, Stam AH, Lighthart L, Wedenjoja N, Dunham I, Neale BM, Palta P, Hamalainen E, Schurks M, Rom L, Buring JE, Ridker PM, Steinberg S, Stefansson H, Jakobsson F, Lawlor DA, Evans DM, Ring SM, Farkkila M, Atto V, Kauinfo MA, Freilinger T, Schoenen J, Frants RR, Pelzer N, Weller CM, Zielman R, Heilich AG, Madden PA, Montgomery GW, Martin NG, Borck G, Gobbel H, Heinez A, Heinez-Kuhn K, Williams FM, Hartikainen AL, Pouta A, van den Ende J, Lutterlinde AG, Hofman A, Amin N, Hottinga JJ, Vink JM, Heikila K, Alexander M, Muller-Mynsko B, Schreiber S, Meitinger T, Wichmann HE, Aromaa E, Eriksson JG, Traylor BJ, Trabuzin D, Rossin E, Lage K, Jacobs SB, Gibbs JR, Birney E, Kaprio J, Pennix BW, Boomsma DI, van Duijijn C, Ratakari O, Jarvelin M, Zwart JA, Cherukus L, Strachan DP, Kubisch C, Ferrari MD, van den Maagdenberg AM, Dichgans M, Wessman M, Smith GD, Stefansson K, Daly MJ, Nyholt DR, Chapman DI, Palotie A (2013) Genome-wide meta-analysis identifies new susceptibility loci for migraine. Nat Genet 45(8):912–917. doi:10.1038/ng.2676

Gentile G, Borro M, Lala N, Missori S, Sirmmaco M, Martelletti P (2010) Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain 11(2):151–171. doi:10.1007/s10196-010-0230-3

Palotie A (2013) Genome-wide meta-analysis identifies new susceptibility loci for migraine. Cephalalgia 33(11):2099–2104. doi:10.1177/0333102412451356

Dussor G (2014) Serotonin, SHT1 agonists, and migraine: new data, but old questions still not answered. Curr Opin Support Palliat Care 8(2):137–142. doi:10.1097/SPC.0000000000000044

Ibrahim K, Danser A, Terwindt G, van den Meiracker A, MaasmanVenDenBrink A (2016) A human trigeminovascular biomarker for antimigraine drugs: A randomised, double-blind, placebo-controlled, crossover trial with sumatriptan. Cephalalgia. 33(10):1663–1673.

Baiulli LD, Ahn AH, Mulligan SJ (2012) Sumatriptan inhibition of N-type calcium channelmediated signaling in dorsal CGRP terminal fibres. Neuropharmacology 63(3):362–367. doi:10.1016/j.neuropharm.2012.04.016

Evans MS, Cheng X, Jeffry JA, Disney KE, Premkumar LS (2012) Sumatriptan inhibits TRP1 channels in trigeminal neurons. Headache 52(5):773–784. doi:10.1111/j.1526-4610.2011.02053.x

Cameron C, Kelly S, Hiseh S-C, Murphy M, Chen L, Kotb A, Peterson J, Coyle D, Skidmore B, Gomes T, Clifford T, Wels G (2015) Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache 55:221–235. doi:10.1111/head.12601

Gasparini et al. The Journal of Headache and Pain (2017) 18:20 Page 19 of 24
Anthony M, Lance JW (1969) Monoamine oxidase inhibition in the treatment of migraine. Arch Neurol 21(3):263–268

Tielt-Hansen PC, Pihl T, Hougaard A, Mitsikostas DD (2014) Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs. Expert Opin Investig Drugs 23(3):375–385. doi:10.1517/13546109.2014.681817

Farkkila M, Diener H-C, Geraud G, Lainez M, Schoenen J, Hanner N, Pilgrim A, Reuter U (2012) Efficacy and tolerability of lamidatan, an oral 5-HT1(F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 11(5):403–413. doi:10.1016/S1474-4422(12)70047-9

Viguer F, Michot B, Hamon M, Bourgon S (2013) Multiple roles of serotonin in pain control mechanisms. —implications of 5-HT7 and other 5-HT receptor types. Eur J Pharmacol 716(1–3):18, https://dx.doi.org/10.1016/j.ejphar.2013.01.074

Guo W, Miyoshi K, Dubner R, Gu M, Li M, Liu J, Yang J, Zou S, Ren K, Noguchi K, Wei F (2014) Spinal 5-HT3 receptors mediate descending facilitation and contribute to behavioral hypersensitivity via a reciprocal neuron-glial signaling cascade. Mol Pain 10:235. doi:10.1186/1474-4821-10-35

Hlaaar ME, Fisher PM, Jensen CG, Frokjaer VG, Mahon BM, Madsen K, Baare WF, Lehel S, Nonremolle A, Rabiner EA, Knudsen GM (2014) Central 5-HT4 receptor binding as biomarker of serotonergic tonus in humans: a [11C]SB207145 PET study. Mol Psychiatry 19(4):427–432. doi:10.1038/mp.2013.147

Vaseli MS, Yang K, Li J, Kru JS, Heikila JJ, Jackson MS, Mac Donald, JD, Beaazey MA (2013) Acute 5-HT7 receptor activation increases NMDA-evoked currents and differentially alters NMDA receptor subunit phosphorylation and trafficking in hippocampal neurons. Mol Brain 6(1):1–9. doi:10.1186-1756-6606-6-24

Cho SY, Kh IG, Kim JM, Oh JH, Yoon WM, Choi JI (2015) Expression of the spinal 5-HT7 receptor and p-ERK pathway in the carangiainic inflammatory pain of rats. Korean J Anesthesiol 68(2):170–174. doi:10.1016/j.kjae.2015.08.170

Helund LB (2009) The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl) 206(3):345–354

Jenkins TA, Nguyen JCD, Nguyen JCD, Polglaze KE, Bertrand PP (2016) Influence of carageenan inflammatory pain of rats. Korean J Anesthesiol 68(2):170–174. doi:10.1016/j.kjae.2015.08.170

Richard DM, Dawes MA, Mathias CW, Acheson A, Hill-Kapturczak N, Datta S, White S, Jenkins TA, Nguyen JCD, Polglaze KE, Bertrand PP (2016) Influence of carageenan inflammatory pain of rats. Korean J Anesthesiol 68(2):170–174. doi:10.1016/j.kjae.2015.08.170

Jenkins TA, Nguyen JCD, Polglaze KE, Bertrand PP (2016) Influence of carageenan inflammatory pain of rats. Korean J Anesthesiol 68(2):170–174. doi:10.1016/j.kjae.2015.08.170

Young SN (2013) Acute tryptophan depletion in humans: a review of theoretical, practical and ethical aspects. J Psychiatr Neurosci 38(5):294–305. doi:10.1503/jpn.120209

Young SN (2007) How to increase serotonin in the human brain without drugs. J Psychiatr Neurosci 32(6):394–399

Rao TSS, Asha MR, Ramesh BN, Rao KSJ (2008) Understanding nutrition, depression and mental illnesses. Indian J Psychiatry 50(2):77–82. doi:10.4103/0019-5545.42391

Wuttman RJ (1987) Dietary treatments that affect brain neurotransmitters. Ann N Y Acad Sci 499(1):179–190. doi:10.1111/j.1749-6632.1987.tb36209.x

Drummond PD (2006) Tryptophan depletion increases nausea, headache and photophobia in migraine sufferers. Cephalalgia 26(10):1225–1233. doi:10.1111/j.1468-2982.2006.01212.x

Kangasniemi P, Fack G, Langvik YA, Hyypia MT (1978) L-Tryptophan treatment in migraine. Headache 18(3):161–165

Steardo L, Sorge F, Florio C (1977) L-Tryptophan treatment in essential headache: preliminary data. Acta Neurop (Napoli) 32(5):613–623

Shabbir F, Patel A, Mattison C, Bose S, Krishnamohan R, Sweeney E, Sandhu S, Niel W, Nais A, Sandhu R, Ngu N, Sharma S (2013) Effect of diet on serotonergic neurotransmission in depression. Neurochem Int 62(3):324–329. doi:10.1016/j.neuint.2012.12.014

Gyemrek L (1996) Pharmacology of serotonin as related to anesthesia. J Clin Anesth 8(5):402–425

Claustro B, Loisy C, Brun J, Beorchia S, Annau JL, Chazot G (1989) Nocturnal plasma melatonin levels in migraine - a preliminary report. Headache 29(4):242−245. doi:10.1111/j.1526-4610.1989.tb22042.x

Clagnel G, Foraz S, Coster M, Solinas GP, Parodi C, Marabini S, Fanciullacci M, Polder M (1994) Urinary melatonin excretion throughout the ovarian cycle in menstrual related migraine. Cephalalgia 14(3):205–209. doi:10.1086/1468-2982.1994.0014003205.x

Brun J, Claustro B, Saddier P, Chazot G (1995) Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. Cephalalgia 15(2):136–139. doi:10.1080/014614819501500136x

Bruea O, Sarcos G, Leston J, Levin G, Cristina S, Medina C, Barontin M, Nappi G, Figureola MA (2008) Plasma melatonin pattern in chronic and episodic headaches: evaluation during sleep and waking. Funct Neurol 23(2):77–81

Peres MF, Sanchez del Rio M, Seabra ML, Tufi S, Abucham J, Cipolla-Neto J, Silberstein SD, Zukerman E (2001) Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry 71(6):747–751

Maruha MR, de Souza Vieira DS, Minett TS, Cipolla-Neto J, Zukerman E, Vilanova LC, Peres MF (2008) Low urinary 6-sulphatoxymelatonin concentrations in acute migraine. J Headache Pain 9(4):221–224. doi:10.1007/s10194-008-0047-5

Maruha MR, Lin J, de Souza Vieira DS, Minett TS, Cipolla-Neto J, Zukerman E, Vilanova LC, Peres MF (2010) Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and some comorbidities. Headache 50(5):413–419. doi:10.1111/j.1526-4610.2009.01547.x

Singh M, Jadhav HR (2014) Melatonin: functions and ligands. Drug Discov Today 19(9):1410–1418. doi:10.1016/j.drudis.2014.04.014

Badawy A (2013) Novel nutritional treatment for manic and psychotic disorders: a review of tryptophan and tyrosine depletion studies and the treatment of manic episodes. J Psychiatr Res 47(8):1058–1070. doi:10.1016/j.jpsychires.2013.04.006
potential of protein-based formulations using glycomacropeptide. Psychopharmacology (Berl) 228(3):347–358. doi:10.1007/s00213-013-3191-9

116. Lu WZ, Gwee KA, Mookchhala S, Ho KY (2005) Melatonin improves bowel symptoms in female patients with irritable bowel syndrome: a double-blind placebo-controlled study. Aliment Pharmacol Ther 22(10):927–934. doi:10.1111/j.1365-2036.2005.02673.x

117. de Zanette SA, Vercellino R, Laste G, Roszyk JR, Schwertner A, Machado CB, Xavier F, de Souza ICC, Deitos A, Torres IL, Caumo W (2014) Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacol Toxicol 15:1–14. doi:10.1186/s40251-020-0051-6

118. Andersen LP, Gogenur I, Rosenberg J, Reiter RJ (2016) The safety of melatonin-GABA-beta-hydroxytryptophan formulation for pediatric migraine prophylaxis. Curr Drug Saf 10(2):132–136. doi:10.3109/17552267.2015.1000528

119. Peres MF, Bossio SM, Masruha MR, Zukerman E, Moreira-Filho CA, Cavalheiro EA (2006) Validation of a less-invasive method for measurement of serotonin synthesis rate in vivo. J Cereb Blood Flow Metab 17(6):659–669. doi:10.1097/00004647-199706000-00007

120. Bocca F, Spadavecchia A, Lusis V, Avramidis T, Thomaidis T (2016) Melatonin 4 mg as prophyllactic therapy for primary headaches: a pilot study. Funct Neurol 31(1):33–37

121. Members: IHCTTS, Teltl-Hansen P, Pascual J, Ramadan N, Dählöf C, D’Amico D, Diener H-C, Jäntti-Miian, M. Loder E, McCrory D, Panclade S, Schwedt T (2012) Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia 32(1):18–38. doi:10.1177/0333102411417901

122. Peres MF, Zukerman E, da Cunha TF, Moreira FR, Cipolla-Neto J (2004) Melatonin, 3 mg, is effective for migraine prevention. Neurology 63(4):757–759

123. Miano S, Parisi P, Pelliccia A, Luchetti A, Paolino MC, Villa MP (2008) Melatonin to prevent migraine or tension-type headache in children. Neurol Sci 29(4):285–287

124. Alstadhau KG, Odeh F, Salvesen R, Bekkelund SI (2010) Prophylaxis of migraine with melatonin: a randomized controlled trial. Neurology 75(17):1527–1532. doi:10.1212/01.wnl.000038119618c

125. Fallah R, Shorofki FF, Ferdosian F (2015) Safety and efficacy of melatonin in pediatric migraine prophylaxis. Curr Drug Saf 10(2):132–135

126. Jones RS (1982) Tryptamine: a neuromodulator or neurotransmitter in mammalian brain? Prog Neurobiol 1(1):1–127

127. Mousset D (1993) Tryptamine: a metabolite of tryptophan implicated in various neuropsychiatric disorders. Metab Brain Dis 8(1):1–44. doi:10.1007/bf01000528

128. D’Andrea G, D’Amico D, Bussone G, Bolner A, Aguglia M, Saracco MG, Galloni E, De Riva V, D’Arigo A, Colavito D, Leon A, Perini F (2014) Tryptamine levels are low in plasma of chronic migraine and chronic tension-type headache. Cephalalgia 34(3):165–173. doi:10.1177/0333102413481030

129. D’Andrea G, Cevoli S, Colavito D, Leon A (2015) Biochemistry of primary headaches: role of tyrosine and tryptophan metabolism. Neurosci Lett 57(1):678–682. doi:10.1016/j.neulet.2015.04.015

130. D’Andrea G, D’Amico D, Bussone G, Bolner A, Aguglia M, Saracco MG, Galloni E, De Riva V, D’Arigo A, Colavito D, Leon A, Rosteghin V, Perini F (2013) The role of tyrosine metabolism in the pathogenesis of chronic migraine. Cephalalgia 33(11):932–937. doi:10.1177/0333102413480755

131. D’Andrea G, Leone M, Bussone G, Fiore PD, Bolner A, Aguglia M, Saracco MG, Perini F, Giordano G, Guacciardi A, Leon A (2016) Abnormal tyrosine metabolism in chronic cluster headache. Cephalalgia. doi:10.1177/0333102416640502

132. Stahl SM (1977) The human platelet. A diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders. Arch Gen Psychiatry 34(5):509–516

133. Gerring Z, Rodriguez-Acevedo AJ, Powell JE, Griffiths LR, Montgomery GW, Nyholt DR (2016) Blood gene expression studies in migraine: potential and caveats. Cephalalgia 36(10):1057–1069. doi:10.1177/0333102416662076

134. Saulin A, Savili M, Lenzenger R (2012) Serotonin and molecular neuroimaging in humans using PET. Amino Acids 42(8):2039–2057

135. Paterson LM, Kornum BR, Natt D, Pike WJ, Knudsen GM (2013) 5-HT radioligands for human brain imaging with PET and SPECT. Med Res Rev 33(1):54–111. doi:10.1002/med.20245

136. Fumita M, Robert B In vivo molecular imaging: ligand development and research applications. In: in Neuropsychopharmacology: The Fifth Generation of Progress, 2000. Citerese,
226. Herman F, Magyar K, Kovacs K, Filep J (1989) Decreased sensitivity of
225. D
224. D
223. Kozubski W, Walkowiak B, Cierniewski CS, Prusinski A (1987) Platelet
221. Shukla R, Shanker K, Nag D, Verma M, Bhargava KP, (1987) Serotonin in
220. Lingjaerde O, Monstad P (1986) The uptake, storage, and efflux of serotonin
219. Lechner H, Ott E, Fazekas F, Pilger E (1985) Evidence of enhanced platelet
218. Kruglak L, Nathan I, Korczyn AD, Zolotov Z, Berginer V, Dvilansky A (1984)
217. Pradalier A, Launay JM, Dry J, Dreux C (1983) Role of platelet serotonin in

208. Bouatra S, Aziat F, Mandal R, Guo AC, Wilson MR, Knox C, Bjorndahl TC,
206. Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, Cheng D, Jewell K,

Gasparini et al. The Journal of Headache and Pain (2017) 18:20
Page 23 of 24

221 - 222

225. D

208. Bouatra S, Aziat F, Mandal R, Guo AC, Wilson MR, Knox C, Bjorndahl TC,
206. Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, Cheng D, Jewell K,

Gasparini et al. The Journal of Headache and Pain (2017) 18:20
Page 23 of 24

221 - 222

208. Bouatra S, Aziat F, Mandal R, Guo AC, Wilson MR, Knox C, Bjorndahl TC,
206. Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, Cheng D, Jewell K,
254. Zeller JA, Lindner V, Frohm K, Baron R, Deuschl G (2005) Platelet activation and platelet-leucocyte interaction in patients with migraine. Subtype differences and influence of triptans. Cephalalgia 25(7):536–541. doi:10.1111/j.1468-2982.2005.00916.x

255. Taffi R, Vignini A, Lanciotti C, Luconi R, Nanetti L, Mazzanti L, Provinciali L, Silvestrini M, Bartolini M (2005) Platelet membrane fluidity and peroxynitrite levels in migraine patients during headache-free periods. Cephalalgia 25(5):353–358. doi:10.1111/j.1468-2982.2004.00863.x

Submit your manuscript to a SpringerOpen journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ➤ springeropen.com